Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 mars 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Newly Issued Japanese Patent For PDC Optical Agents Further Strengthens Cellectar Biosciences’ Intellectual Property Portfolio

MADISON, Wis., March 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the Japanese...
09 mars 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host Conference Call on March 15 to Report Fourth Quarter and Year-End 2016 Financial Results and Corporate Performance

MADISON, Wis., March 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the “company”), an oncology-focused, clinical stage biotechnology company, today announces that...
08 mars 2017 08h00 HE | Source: Cellectar Biosciences, Inc.

Expanding Its Strategic Relationship with Wisconsin Alumni Research Foundation (WARF), Cellectar Biosciences Executes New License Agreement

MADISON, Wis., March 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces it has entered...
06 mars 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at 29th Annual Roth Conference

MADISON, Wis., March 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO,...
27 févr. 2017 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Provides Phase I Trial Update of CLR 131 in Multiple Myeloma: Median Progression-Free Survival Extends to 133 Days, Median Overall Survival Reaches 17.7 Months

MADISON, Wis., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today provides an update of its Phase I clinical...
22 févr. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Upon Successful Completion of Cohort 3, Cellectar Biosciences Initiates Fourth Cohort of Its Phase I Clinical Trial of CLR 131 in Multiple Myeloma

MADISON, Wis., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the successful completion of...
13 févr. 2017 07h00 HE | Source: Cellectar Biosciences, Inc.

UPDATE -- Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

MADISON, Wis., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim...
07 févr. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO,...
31 janv. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform

MADISON, Wis., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, today announces the advance...
26 janv. 2017 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at NobleCon13

MADISON, Wis., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim...

Page précédente